ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.805 USD
-3.32%
Updated:
Apr 24, 2024
ADC Therapeutics SA
Cash from Financing Activities
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Cash from Financing Activities Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Financing Activities
$73.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash from Financing Activities
CHf43.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Financing Activities
$62.7m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Financing Activities
-CHf57.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-20%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Financing Activities
CHf162.3m
|
CAGR 3-Years
396%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Financing Activities
-CHf171k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Cash from Financing Activities?
Cash from Financing Activities
73.9m
USD
73.9m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cash from Financing Activities amounts to 73.9m USD.
What is ADC Therapeutics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-47%
-47%
The average annual Cash from Financing Activities growth rates for ADC Therapeutics SA have been -47% over the past three years .
You don't have any saved screeners yet
